Dr. Harry Greenberg is the associate dean for research and professor of medicine, microbiology, and immunology at Stanford. He is co-director of the Stanford Clinical and Translational Science Award (CTSA). His research involves viruses that infect the gastrointestinal tract, lungs, and liver with a focus on rotaviruses, viral pathogenesis and immunity. He has published more than 470 primary research, reviews, and book chapters. He was an inventor of the first licensed rotavirus vaccine. He was also part of teams that developed the ROTAVAC® vaccine recently licensed in India. His research also involved studies of noroviruses, hepatitis B and C, and influenza. Dr. Greenberg received his medical degree from Columbia College of Physicians and Surgeons, completed a residency in internal medicine at Bellevue, and a fellowship in gastroenterology at Stanford. He was a medical officer in the Laboratory of Infectious Diseases at the National Institutes for Health for nine years before joining Stanford in 1983. Dr. Greenberg served as chief of the Stanford Division of Gastroenterology, as associate chief of staff for research at the Palo Alto VA, and as acting chair of the Stanford Department of Medicine twice.
He has been elected to several scholarly societies including the American Society for Clinical Investigation, the Association of American Physicians, and the American Association for the Advancement of Science (AAAS). He was a president of the American Society of Virology, served as the chair of the Food and Drug Administration Advisory Committee on Vaccines and Related Biologics, and as chair of the Medical Sciences Section of AAAS. During a leave of absence from Stanford, he was the chief scientific officer at Medimmune Vaccines where he helped develop and license a live attenuated influenza vaccine.
Harry B. Greenberg, MD Presentations
June 19, 2020 at 12:30 PM - 1:45 PM
The late stage development of vaccines for global health use are challenged by complex and costly clinical studies in low-income settings and unclear financial markets. This session will describe the development strategies and partnerships that support the development of malaria, typhoid, and rotavirus vaccines.